CN1167710C - 吡咯烷羰基氨基环状二硫化物 - Google Patents

吡咯烷羰基氨基环状二硫化物 Download PDF

Info

Publication number
CN1167710C
CN1167710C CNB008064601A CN00806460A CN1167710C CN 1167710 C CN1167710 C CN 1167710C CN B008064601 A CNB008064601 A CN B008064601A CN 00806460 A CN00806460 A CN 00806460A CN 1167710 C CN1167710 C CN 1167710C
Authority
CN
China
Prior art keywords
compound
acceptable salts
amino
pharmacologically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008064601A
Other languages
English (en)
Chinese (zh)
Other versions
CN1347419A (zh
Inventor
陈力
ϣ
纳德尔·福图希
����ſ���
达维德·扬·雅克松
���ء����߸�
杰斐逊·赖特·蒂利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1347419A publication Critical patent/CN1347419A/zh
Application granted granted Critical
Publication of CN1167710C publication Critical patent/CN1167710C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNB008064601A 1999-04-20 2000-04-17 吡咯烷羰基氨基环状二硫化物 Expired - Fee Related CN1167710C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13021599P 1999-04-20 1999-04-20
US60/130,215 1999-04-20

Publications (2)

Publication Number Publication Date
CN1347419A CN1347419A (zh) 2002-05-01
CN1167710C true CN1167710C (zh) 2004-09-22

Family

ID=22443611

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008064601A Expired - Fee Related CN1167710C (zh) 1999-04-20 2000-04-17 吡咯烷羰基氨基环状二硫化物

Country Status (15)

Country Link
US (1) US6265572B1 (cg-RX-API-DMAC7.html)
EP (1) EP1171452B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002542256A (cg-RX-API-DMAC7.html)
KR (1) KR100636481B1 (cg-RX-API-DMAC7.html)
CN (1) CN1167710C (cg-RX-API-DMAC7.html)
AR (1) AR023546A1 (cg-RX-API-DMAC7.html)
AT (1) ATE337331T1 (cg-RX-API-DMAC7.html)
AU (1) AU769294B2 (cg-RX-API-DMAC7.html)
BR (1) BR0009838A (cg-RX-API-DMAC7.html)
CA (1) CA2370259A1 (cg-RX-API-DMAC7.html)
DE (1) DE60030266T2 (cg-RX-API-DMAC7.html)
ES (1) ES2269141T3 (cg-RX-API-DMAC7.html)
TR (1) TR200103004T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000063234A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200108018B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939855B2 (en) * 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US20090043126A1 (en) * 2005-02-28 2009-02-12 Jordi Bosch I Llado Process and Methods for the Preparation of Gabapentin and Its Intermediates
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2013057096A1 (en) 2011-10-17 2013-04-25 Westfaelische Wilhelms-Universitaet Muenster Assessment of pml risk and methods based thereon
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds

Also Published As

Publication number Publication date
DE60030266D1 (de) 2006-10-05
EP1171452B1 (en) 2006-08-23
DE60030266T2 (de) 2007-07-19
US6265572B1 (en) 2001-07-24
WO2000063234A2 (en) 2000-10-26
KR20010108517A (ko) 2001-12-07
ES2269141T3 (es) 2007-04-01
KR100636481B1 (ko) 2006-10-18
CN1347419A (zh) 2002-05-01
CA2370259A1 (en) 2000-10-26
TR200103004T2 (tr) 2002-01-21
WO2000063234A3 (en) 2001-01-18
AR023546A1 (es) 2002-09-04
EP1171452A2 (en) 2002-01-16
AU769294B2 (en) 2004-01-22
AU4748200A (en) 2000-11-02
ZA200108018B (en) 2003-03-26
BR0009838A (pt) 2002-01-08
JP2002542256A (ja) 2002-12-10
ATE337331T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
CN1084743C (zh) 毒蕈碱拮抗剂
CN1088456C (zh) 取代的噁唑烷需钙蛋白酶和/或组织蛋白酶b抑制剂
CN1105723C (zh) 螺环金属蛋白酶抑制剂
CN1656077A (zh) 制备手性二醇砜和二羟基酸HMGCoA还原酶抑制剂的方法
CN1040986A (zh) 环烷基取代的戊二酰胺衍生物的制备
CN1344160A (zh) 用作生长激素促分泌剂的杂环芳族化合物
CN1276785A (zh) N-烷酰基苯丙氨酸衍生物
CN1106003A (zh) 微粒体甘油三酯转移蛋白的抑制剂和方法
CN1688544A (zh) 作为蕈毒碱受体拮抗剂的含氟代和磺酰氨基的3,6-二取代的氮杂双环(3.1.0)己烷衍生物
CN1418193A (zh) 含有杂环侧链的金属蛋白酶抑制剂
CN1228772A (zh) 杂环金属蛋白酶抑制剂
CN1281430A (zh) 芳酰基苯丙氨酸衍生物
CN1342140A (zh) 硫代酰胺衍生物
CN1083062A (zh) 异羟肟酸衍生物
CN86105870A (zh) 带5-氨基-2,5-二取代-4-羟基戊酸基的血管紧张肽原酶抑制剂
CN1061971A (zh) 可用作脑啡肽酶和血管紧张素转化酶抑制剂的新巯基乙酰基酰胺衍生物
CN1735597A (zh) 作为前列腺素激动剂的2-哌啶酮衍生物
CN1229335C (zh) 莫维诺林衍生物
CN1324008C (zh) 作为组织蛋白酶抑制剂的新化合物和组合物
CN1127488C (zh) 具有生长激素释放特性的化合物
CN1119328C (zh) 作为nk1和nk2拮抗剂的酰氨基亚链烯基酰胺衍生物
CN1347419A (zh) 吡咯烷羰基氨基环状二硫化物
HK1042691A1 (zh) 磺酰胺异羟肟酸脂
CN1025676C (zh) 非肽的血管紧张肽原酶抑制剂的制备
CN1575282A (zh) 内酰胺化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040922